ASCO 2022 Kidney Cancer

Viewing 1-19 of 19 articles

ASCO 2022: Sequencing Challenges in Renal Cell Carcinoma: What to Do Next? - Discussion

ASCO 2022: Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma - Discussion

ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426

ASCO 2022: Sequential Immunotherapy in Rare Variant Renal Cell Carcinoma Final Report of UNISoN (ANZUP 1602): Nivolumab Then Ipilimumab + Nivolumab in Advanced Nonclear Cell Renal Cell Carcinoma

ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations

ASCO 2022: Outcomes With Novel Combinations in Non-Clear Cell RCC: ORACLE Study

ASCO 2022: The Prognostic Role of Nephrectomy in Patients With mRCC Treated With Immunotherapy According to the Novel Prognostic Meet-URO Score: Sub-Analysis of the Meet-URO 15 Study

ASCO 2022: Prognostic Value of the Lung Immune Prognostic Index in Patients With Untreated Advanced RCC Receiving Nivolumab + Ipilimumab or Sunitinib in the CheckMate 214 Trial

ASCO 2022: Prognostic Factors for Patients With Advanced RCC in the Era of First-Line Treatment With Immune Checkpoint Inhibitors

ASCO 2022: Distinct Outcomes in Hispanic/Latinx and Non-Hispanic/Latinx Patients With Metastatic RCC Treated With First-Line Ipilimumab + Nivolumab

ASCO 2022: Healthcare Resource Utilization and Costs for Patients With mRCC Receiving First-Line Pembrolizumab + Axitinib or Ipilimumab + Nivolumab

ASCO 2022: Racial Differences in Treatment Patterns and Outcomes of First-Line Therapies for Advanced RCC in the Real-World Setting

ASCO 2022: LITESPARK-004 (MK-6482-004) Phase 2 Study of Belzutifan, an Oral HIF-2α Inhibitor, for Von Hippel-Lindau Disease: Update With More Than Two Years of Follow-Up Data

ASCO 2022: PSMA PET-CT for Advanced Renal Cell Carcinoma

ASCO 2022: Are We Improving Outcomes Comprehensively in Renal Cell Carcinoma? - Discussion

ASCO 2022: The Relationship Between Health-Related Quality of Life (HRQoL) and Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma (aRCC) in CheckMate (CM) 214

ASCO 2022: CALYPSO: A Three-Arm Randomized Phase II Study of Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer

ASCO 2022: Association Between Depth of Response (DepOR) and Clinical Outcomes: Exploratory Analysis in Patients with Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 9ER

ASCO 2022: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy—A Phase III Study (SWOG S0931)